Adlai Nortye Ltd. American Depositary Shares (ANL) - Cash Flow Conversion Efficiency
Based on the latest financial reports, Adlai Nortye Ltd. American Depositary Shares (ANL) has a cash flow conversion efficiency ratio of 4.020x as of March 2026. Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($-33.45 Million) by net assets ($-8.32 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations. Also see how much is Adlai Nortye Ltd. American Depositary Sh worth for the company's overall valuation and market capitalisation.
Adlai Nortye Ltd. American Depositary Shares - Cash Flow Conversion Efficiency Trend (2019–2025)
This chart illustrates how Adlai Nortye Ltd. American Depositary Shares's cash flow conversion efficiency has evolved over time, based on yearly financial data.
Adlai Nortye Ltd. American Depositary Shares Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Adlai Nortye Ltd. American Depositary Shares ranked by their cash flow conversion efficiency. See how well can Adlai Nortye Ltd. American Depositary Sh service its debt to evaluate how effectively operating cash flow covers total debt obligations.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
Heritage Commerce Corp
NASDAQ:HTBK
|
0.028x |
|
Theravance Biopharma Inc
F:0TB
|
-0.028x |
|
HIT Welding Industry Co. Ltd.
SHE:301137
|
0.038x |
|
Nesco Limited
NSE:NESCO
|
0.072x |
|
Anhui Sierte Fertilizer Industry Ltd Co
SHE:002538
|
0.024x |
|
Abacus Life Inc.
NASDAQ:ABL
|
-0.075x |
|
Vulcabras Azaleia S.A
SA:VULC3
|
0.055x |
|
Guizhou Xinbang Pharmaceutical Co Ltd
SHE:002390
|
0.034x |
Annual Cash Flow Conversion Efficiency for Adlai Nortye Ltd. American Depositary Shares (2019–2025)
The table below shows the annual cash flow conversion efficiency of Adlai Nortye Ltd. American Depositary Shares from 2019 to 2025. View ANL live share price for real-time trading data and today's change.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2025-12-31 | $-8.32 Million | $-33.54 Million | 4.030x | +298.21% |
| 2024-12-31 | $25.48 Million | $-51.82 Million | -2.033x | -169.35% |
| 2023-12-31 | $75.05 Million | $-56.65 Million | -0.755x | -521.42% |
| 2022-12-31 | $-241.29 Million | $-43.22 Million | 0.179x | +994.79% |
| 2021-12-31 | $-185.43 Million | $-3.03 Million | 0.016x | -93.78% |
| 2020-12-31 | $-131.56 Million | $-34.59 Million | 0.263x | +22.25% |
| 2019-12-31 | $-69.38 Million | $-14.92 Million | 0.215x | -- |
About Adlai Nortye Ltd. American Depositary Shares
Adlai Nortye Ltd., a clinical-stage company, together with its subsidiaries, engages in the research and develops pharmaceutical products. Its product pipeline comprises AN0025, a small molecule EP4 antagonist which is in phase Ib and radiotherapy/chemoradiotherapy combination for the treatment of rectum cancer and esophageal cancer; and phase II trial for patients with moderate to high-risk rect… Read more